Archived Medical News Stories

RSSArchived Drug Trial News Stories - February 2010

Date Title Comments Rating
2010-02-27 ADMET tester Absorption Systems joins Society of Toxicology as Affiliate 0 4
2010-02-27 Single submission of orphan drug designation annual report for both FDA and EMA 0 2
2010-02-27 Synta Pharmaceuticals presents preclinical and clinical data of Hsp90 inhibitor STA-9090 0 None
2010-02-26 Teva Pharmaceutical announces clinical study results of Copaxone in RRMS patients 0 None
2010-02-26 Antiretroviral therapy reduces mortality rates in patients co-infected with HIV and TB 0 None
2010-02-26 Study confirms efficacy and tolerability of lacosamide for uncontrolled POS 0 None
2010-02-26 Resverlogix commences enrollment in RVX-208 Phase 2 clinical trial for atherosclerosis in ACS patients 0 5
2010-02-26 Genta initiates new dose-ranging study of tesetaxel drug 0 None
2010-02-25 Kinex Pharmaceuticals announces KX2-391 Phase 2 safety and efficacy clinical trial in men with CRPC 0 None
2010-02-25 Cannabis Science completes selection of initial cannabis-based pharmaceutical for FDA clinical trials 0 None
2010-02-25 OncoGenex Pharmaceuticals receives CHMP advice on OGX-011 development plan in treatment of mCRPC 0 None
2010-02-25 Study demonstrates Prochymal treamtent is safe for cardiac patients 0 None
2010-02-25 Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy 0 None
2010-02-25 Anadys Pharmaceuticals' ANA598 combination demonstrates 73% cEVR in ongoing Phase II study for HCV 0 None
2010-02-24 Welichem commences enrollment in WBI-1001 Phase IIa clinical trial for psoriasis 0 None
2010-02-24 Enzon Pharmaceuticals initiates treatment in PEG-SN38 Phase 1 study for pediatric cancer patients 0 None
2010-02-24 Novelos Therapeutics' NOV-002 Phase 3 NSCLC trial fails to meet primary survival endpoint 0 None
2010-02-24 Phase III trial results of Osiris Therapeutics' Prochymal for GvHD to be presented at BMT Tandem Meeting 0 5
2010-02-24 Idera Pharmaceuticals presents IMO-3100 TLR antagonist mechanism of action data at Keystone conference 0 None
2010-02-24 ViiV Healthcare highlights S/GSK1349572, SELZENTRY and EPZICOM for HIV/AIDS at 17th CROI 0 5
2010-02-24 Enrollment complete in Ocera Therapeutics' ASTUTE Phase 2B trial for mild hepatic encephalopathy 0 None
2010-02-23 Catalyst Pharmaceutical Partners, NIDA partner to conduct CPP-109 Phase II(b) clinical trial for cocaine addiction 0 4.5
2010-02-23 Aradigm initiates dosing in Phase 2b trial of inhaled liposomal ciprofloxacin formulations in BE patients 0 None
2010-02-23 Lexicon Pharmaceuticals reports positive results from Phase 2 clinical trials for IBS and type 2 diabetes 0 None
2010-02-23 TCAD therapy active and synergistic against drug resistant influenza virus strains 0 None
2010-02-23 Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint 0 None
2010-02-23 GlycoVaxyn initiates Phase I clinical study of GVXN SD133 vaccine candidate against Shigella dysenteriae 0 None
2010-02-23 Viamet Pharmaceuticals, Novartis Option Fund partner to develop novel inhibitors against key metalloenzyme target 0 None
2010-02-23 Heartware completes patient enrollment for ADVANCE clinical trial 0 None
2010-02-23 Merrimack Pharmaceuticals commences dosing in MM-121/Tarceva combination Phase 1/2 study for NSCLC 0 None
2010-02-23 Amylin Pharmaceuticals and Takeda Pharmaceutical to advance pramlintide/metreleptin combination therapy development 0 None
2010-02-22 Enzymerx completes enrollment for clinical trial of pegsitacase 0 None
2010-02-22 FDA grants Fast Track designation for Curemark's CM-AT autism treatment 0 None
2010-02-22 Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection 0 None
2010-02-20 Emory School of Medicine to enroll nearly 1,140 people for Phase III clinical trial of progesterone for TBI 0 None
2010-02-19 Polyphor discovers new class of antibiotics effective against multi-drug resistant Gram-negative bacteria 0 None
2010-02-19 BioCrossroads' Indiana Seed Fund invests $400,000 in Bioscience Vaccines 0 None
2010-02-19 Data from Novavax's Pivotal 2009 A/H1N1 VLP pandemic influenza vaccine study presented at WHO meeting 0 None
2010-02-19 BioSante Pharmaceuticals' LibiGel clinical update to be presented at 2010 ISSWSH annual meeting 0 None
2010-02-18 Incyte announces 2009 financial results and key fourth-quarter accomplishments 0 None
2010-02-18 Phase 2 study results: VEGF Trap-Eye improves vision in patients with DME 0 None
2010-02-18 PK/PD data demonstrates clear relationship between TBR-652 plasma concentrations and antiviral activity 0 None
2010-02-18 Aprea's AML treatment receives EMEA recommendation for orphan drug status 0 None
2010-02-18 Gilead Sciences’ “Quad” regimen for HIV exhibits antiretroviral activity comparable to Atripla 0 None
2010-02-18 Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers 0 None
2010-02-18 Phase 3b ODIN study of once-daily PREZISTA in HIV-1 adults presented at CROI 2010 0 None
2010-02-17 Roche completes enrollment in RG7128 Phase 2b PROPEL study 0 None
2010-02-17 Tioga Pharmaceuticals to utilize $18M equity funding for Phase 3 clinical trial of asimadoline 0 None
2010-02-17 FDA clears Otonomy's IND for clinical trial of OTO-104 in Meniere's disease patients 0 4.2
2010-02-17 Marcadia Biotech commences Phase 1 clinical trial of MAR701 for type 2 diabetes 0 None
2010-02-17 Fourth-quarter and full-year 2009 results announced by Celsion 0 None
2010-02-17 Phase III study: GARDASIL prevents 77.5% of pre-cursor lesions to anal cancer 0 None
2010-02-17 Phase II clinical trial result of abiraterone drug shows promise for advanced prostate cancer 0 5
2010-02-17 ITS secures £8.65M Series-A equity funding round extension to fund synthetic flu vaccine study 0 None
2010-02-17 Generx clinical development opportunities: bioRASI to assist Cardium 0 None
2010-02-16 Cancer Research UK, immatics Biotechnologies sign collaboration agreement to trial IMA950 vaccine for GMB 0 None
2010-02-16 Positive topline data from Alkermes' phase 1 clinical study of ALKS 37 announced 0 None
2010-02-16 Oncolytics Biotech receives U.K. MHRA approval for REOLYSIN combination Phase 3 trial 0 3
2010-02-16 MAP Pharmaceuticals initiates LEVADEX-intravenous DHE comparative trial 0 None
2010-02-16 Octapharma initiates Phase III studies for new, high purity IVIG in treatment of primary immune deficiency 0 None
2010-02-14 Positive interim results from Helix BioPharma's Topical Interferon Alpha-2b Phase II pharmacokinetic study 0 None
2010-02-12 Debiopharm receives AFSSAPS approval of CTA for Debio 0932 inhibitor, triggers milestone payment to Curis 0 None
2010-02-12 Viral Genetics: Company update 0 None
2010-02-12 Encouraging results from Circassia's ToleroMune ragweed allergy T-cell vaccine phase II clinical trial 0 None
2010-02-12 Peregrine Pharmaceuticals' Cotara specifically targets solid tumors and anti-tumor activity 1 5
2010-02-12 Third party reexamination of Phase III study of Ereska meets primary endpoint 0 None
2010-02-12 Genzyme announces 2-year data from eliglustat tartrate Phase 2 trial for Gaucher disease 0 None
2010-02-12 Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease 0 None
2010-02-12 NMDP Phase III filgrastim trial: Biologics to provide pharmacy management services 0 None
2010-02-12 Second-quarter fiscal 2010 results announced by Pharmacyclics 0 None
2010-02-12 Additional data from Phase III clinical trial of taliglucerase alfa in patients with Gaucher disease presented 0 None
2010-02-11 Amicus Therapeutics presents additional data from Amigal Phase 2 extension study for Fabry disease 0 None
2010-02-11 PARI Pharma commences enrollment in L-CsA Phase 2b efficacy study 0 None
2010-02-11 3SBio submits application for Phase I clinical trial of NuPIAO to the Chinese SFDA 0 None
2010-02-11 YM Biosciences to present JAK1/2 inhibiting small molecule and vascular disrupting agent data at Cancer Conference 0 None
2010-02-11 Biodel's VIAject insulin Phase 3 study results to be presented at international diabetes conference in Basel 0 None
2010-02-11 4SC AG announces the first treatment in Phase I clinical study of 4SC-205 0 None
2010-02-11 Micromet outlines the design of registration study for blinatumomab in ALL 0 None
2010-02-11 MUHC commences clinical trial of Exsulin for type 1 diabetes 0 5
2010-02-11 QRxPharma announces the initiation of second pivotal Phase 3 registration trial of MoxDuo IR 0 None
2010-02-10 Raptor Pharmaceutical to present DR Cysteamine trial data at Lysosomal Disease Network Symposium 0 None
2010-02-10 DMC recommends Celsion to continue its Phase III ThermoDox clinical trial for primary liver cancer 0 None
2010-02-10 Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint 0 None
2010-02-10 Positive results from Naurex's Phase I clinical trial of GLYX-13 reported 0 None
2010-02-10 Alexza Pharmaceuticals announces development and commercialization collaboration with Biovail Laboratories International 0 None
2010-02-10 DMC recommends JV to continue enrolling patients in Phase III clinical trial of StemEx 0 None
2010-02-10 QR Pharma commences clinical trial of Posiphen in early stage AD patients 0 None
2010-02-10 Concomitant use of dexlansoprazole and other PPIs with Plavix: TGRD U.S. initiates trial 0 None
2010-02-10 Johns Hopkins Hospital initiates Phase I trial with Neogenix's NPC-1C 0 4.3
2010-02-10 TI commences Phase IIa clinical trial for its lead molecule in CDH 0 None
2010-02-10 Palatin Technologies completes first cohort dosing in bremelanotide trial for sexual dysfunction 0 5
2010-02-10 Advaxi to receive fund from CRUK for clinical trial of ADXS11-001 0 None
2010-02-10 FDA expands indication for Crestor 0 None
2010-02-09 Thrombogenics announces publication of positive microplasmin Phase II trial results 0 None
2010-02-09 USPTO awards NexBio patent covering sialidase pharmaceutical compositions and methods of treating influenza 0 None
2010-02-09 Debiopharm Group signs exclusive licence agreement with Novartis for alisporivir 0 None
2010-02-09 Resverlogix completes Phase 2 ASSERT trial enrollment 5 months ahead of schedule 0 None
2010-02-09 Denosumab exhibits superiority over Zometa in treatment of prostate cancer men with bone metastases 0 None
2010-02-09 Novavax announces new data from trivalent seasonal influenza VLP vaccine study 0 None
2010-02-09 GeoVax Labs provides updates on HIV-1 vaccine trials 0 None
2010-02-09 Positive data from Cara Therapeutics' peripherally-restricted kappa opioid agonist Phase II trial 0 None
2010-02-09 Genta commences Phase 2 trial of tesetaxel on first subject 0 None
2010-02-09 Teva Pharmaceutical Industries extends marketing rights for laquinimod, includes Nordic and Baltic regions 0 None
2010-02-08 Inovio Biomedical announces additional immunogenicity data from therapeutic cervical cancer vaccine trial 0 None
2010-02-08 Anthera Pharmaceuticals reaches agreement with the FDA on SPA for VISTA-16 clinical study 0 None
2010-02-05 CREON effective in improving CFA and CNA in pediatric patients with EPI due to CF 0 None
2010-02-05 EBMT honours abstract on Defibrotide in Hepatic VOD prevention with the Van Bekkum Award 0 None
2010-02-05 BioTime announces results of independent Hextend study in hemodynamically unstable trauma patients 0 None
2010-02-05 Top-line results from Optimer Pharmaceuticals' second fidaxomicin Phase 3 trial in CDI patients 0 None
2010-02-05 BioMarin announces update on BMN 110 Phase I/II trial for Morquio A Syndrome 0 None
2010-02-05 WORLD Symposium: Protalix Biotherapeutics to present data on taliglucerase alfa Phase III Gaucher disease trial 0 None
2010-02-05 Paloma Pharmaceuticals receives FDA approval to enter Phase I studies with P529 0 None
2010-02-04 Data analysis of Delcath Systems' Phase III trial of melphalan to be commenced 0 None
2010-02-04 Results from three phase two studies show the effectiveness of Tanezumab 1 None
2010-02-04 Shire's clinical study results for treatment of Gaucher disease to be presented at LDN World Symposium 0 None
2010-02-04 Brentuximab vedotin-chemotherapy combination clinical trial for Hodgkin lymphoma announced 0 None
2010-02-04 Recent clinical trials in patients with ALBP show that SOMA 250 mg reduces disability 0 None
2010-02-04 Phase 2a clinical trial results of VX-809 in patients with CF announced 0 None
2010-02-03 Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401 0 None
2010-02-03 Daiichi Sankyo initiates Phase III trial of edoxaban in reducing recurrent VTE complications 0 4
2010-02-03 Adcirca now available in Canada for treatment of pulmonary arterial hypertension 0 None
2010-02-03 MV vaccine prevents TB in people with HIV infection 0 None
2010-02-03 Promising results from Soligenix' RiVax vaccine trials against ricin toxin 0 None
2010-02-03 Repros Therapeutics receives FDA confirmation for initiating Androxal IND 0 None
2010-02-03 Artefill could be viable for lipoatrophy and non-surgical anti-aging enhancement 0 None
2010-02-02 GenSpera’s G-115 anti-cancer drug awarded US patent 0 None
2010-02-02 Vantia Therapeutics initiates Phase IIb trial of VA106483 for nocturia 0 None
2010-02-02 RECOTHROM topical hemostat exhibits low rate of anti-product antibody formation 0 None
2010-02-02 Phase III study evaluating PEP005 Gel for treatment of AK meets primary clinical endpoint 0 None
2010-02-02 Pervasis Therapeutics reaches agreement with FDA on pivotal Phase 3 clinical trial for Vascugel 0 None
2010-02-01 Romark Laboratories commences enrollment in Alinia clinical trial for acute uncomplicated influenza 0 None
2010-02-01 Interim positive data from Phase IIa clinical study of SYN115 for Parkinson’s disease 0 3

Total

132 posts
2 comments
32 raters